<DOC>
	<DOCNO>NCT00649207</DOCNO>
	<brief_summary>This Phase I clinical trial study side effect best dose ABT-888 give together Whole Brain Radiation Therapy ( WBRT ) treat patient brain metastasis .</brief_summary>
	<brief_title>A Phase I Study ABT-888 Combination With Conventional Whole Brain Radiation Therapy ( WBRT ) Cancer Patients With Brain Metastases</brief_title>
	<detailed_description>This Phase 1 , multicenter , dose-escalation study evaluate safety , tolerability pharmacokinetics PARP inhibitor ABT-888 combination conventional whole brain radiation therapy ( WBRT ) treatment subject solid tumor metastatic brain .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Central Nervous System Diseases</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<criteria>Age great equal 18 year . Histologically cytologically confirm nonCNS primary solid malignancy . Pathologically radiographically confirm metastatic disease brain . Subjects nonmeasurable lesion , include leptomeningeal carcinomatosis , eligible . WBRT clinically indicate , exception prophylactic treatment . Karnofsky Performance Status ( KPS ) great equal score 70 . Adequate hematology , renal hepatic function . Both men woman childbearing potential must agree use adequate contraception ( one follow list ) prior study entry , duration study participation 2 month follow completion protocol therapy . Total abstinence sexual intercourse ( minimum one complete menstrual cycle ) A vasectomized partner * Hormonal contraceptive ( oral , parenteral transdermal ) least 3 month prior study drug administration Doublebarrier method ( condom , contraceptive sponge , diaphragm vaginal ring spermicidal jelly cream ) Subject capable understanding comply parameter outline protocol . Subject subject 's legally acceptable representative voluntarily sign date informed consent , approve Independent Ethics Committee ( IEC ) /Institutional Review Board ( IRB ) , prior initiation screen studyspecific procedure . Brain metastases secondary germ cell tumor lymphoma malignancy . Primary central nervous system ( CNS ) neoplasm . Prior concurrent administration follow therapy treatment : Prior treatment WBRT SRS perform less 14 day prior WBRT D1 , schedule occur within 30 day last WBRT session Last dose chemotherapy , immunotherapy , biologic therapy , investigational therapy le 14 day prior WBRT D1 . Bisphosphonates , hormone modification therapy , trastuzumab permit without restriction Unresolved unstable , serious toxicity prior administration another investigational drug and/or prior anticancer treatment . Known seizure disorder ( status epileptic ) uncontrolled , seizure occur great equal 3 time week past month . If female , subject pregnant breastfeeding . Clinically significant uncontrolled major cardiac , respiratory , renal , hepatic , gastrointestinal , hematologic neurological/psychiatric disease disorder , include limited : Active uncontrolled infection Symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia Any illness condition ( ) could exacerbate potential toxicity , confound safety assessment , require exclude therapy management , limit compliance study requirement Unable swallow retain oral medication . Known contraindication enhance MRI CT , include limited : Presence metal object within body cardiac pacemaker , implanted cardiac defibrillator , brain aneurysm clip , cochlear implant , ocular foreign body , shrapnel History immediate delay hypersensitivity reaction contraindication contrast agent include limited gadolinium iodine Previous enrollment study another study involve investigation ABT888 , exception receive single dose study drug . Consideration investigator , reason , subject unsuitable candidate receive ABT888 and/or WBRT .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>WBRT</keyword>
	<keyword>Brain Metastases</keyword>
	<keyword>Radiation</keyword>
	<keyword>ABT-888</keyword>
	<keyword>PARP</keyword>
</DOC>